Jubilant Pharmova Limited

NSE:JUBLPHARMA.NS

1198.7 (INR) • At close September 18, 2024
Overview | Financials

Numbers are in millions (except for per share data and ratios) INR.

202320222021202020192018201720162015201420132012201120102009200820072006200520042003
Revenue 67,02962,19360,591.6559,638.7689,765.3789,970.8874,247.7657,652.7557,004.557,761.3857,216.1351,429.943,031.2634,334.0437,812.7235,179.8424,888.7718,097.1515,053.511,702.658,592.01
Cost of Revenue 47,38618,779.317,869.8817,534.5234,544.738,212.5531,435.1922,521.6923,708.829,184.5626,869.9820,500.4622,317.5613,695.0130,458.0716,395.2611,691.539,689.3512,883.046,611.874,379.41
Gross Profit 19,64343,413.742,721.7742,104.2455,220.6751,758.3342,812.5735,131.0633,295.728,576.8230,346.1530,929.4420,713.720,639.037,354.6518,784.5813,197.248,407.82,170.465,090.784,212.6
Gross Profit Ratio 0.2930.6980.7050.7060.6150.5750.5770.6090.5840.4950.530.6010.4810.6010.1950.5340.530.4650.1440.4350.49
Reseach & Development Expenses 148000185.05202.2182.05161.64131.1671.600000000000
General & Administrative Expenses 02,230.782,457.962,322.62,464.692,675.911,459.121,023.26971.381,235.831,056.47,636.551,917.343,674.6504,223.553,344.072,701.7401,863.61,462.94
Selling & Marketing Expenses 01,526.511,559.241,490.512,318.882,176.81,957.951,331.631,202.871,283.71,608.891,232.821,120.971,624.3101,177.72948.66785.090467.81319.33
SG&A 14,4543,757.294,017.23,813.114,783.574,852.713,417.072,354.892,174.252,519.532,665.298,869.373,038.315,298.9605,401.274,292.733,486.8302,331.411,782.27
Other Expenses 687383.386.967.18115.14125.48226.88159.32109.04134.08113.58175.45-39.5311,595.47670.487,885.883,999.222,567.82316.411,316.531,120.12
Operating Expenses 14,45441,191.534,477.2630,917.5240,341.5137,937.8231,738.1524,398.2723,888.0824,552.5723,065.5622,830.6813,841.1416,894.43670.4813,287.158,291.956,054.65316.413,647.942,902.39
Operating Income 5,1893,748.778,398.3411,442.5312,387.2913,820.5111,074.4210,732.799,407.624,024.257,280.598,098.766,872.563,744.66,684.175,497.434,905.292,353.151,854.051,442.841,310.21
Operating Income Ratio 0.0770.060.1390.1920.1380.1540.1490.1860.1650.070.1270.1570.160.1090.1770.1560.1970.130.1230.1230.152
Total Other Income Expenses Net -3,725-3,470.96-2,093.87-2,731.77-2,258.54-4,782.4-2,483.6-3,356.37-3,564.24-3,621.01-5,207.76-4,687.38-5,731.49-1,338.69-1,505.2-2,531.67-343.98599.89-172.66198.4-343.93
Income Before Tax 1,464277.86,304.478,710.7612,105.319,038.118,590.827,376.425,843.38403.242,072.833,411.381,141.072,405.915,178.972,965.764,561.312,953.041,681.391,641.24966.28
Income Before Tax Ratio 0.0220.0040.1040.1460.1350.10.1160.1280.1030.0070.0360.0660.0270.070.1370.0840.1830.1630.1120.140.112
Income Tax Expense 978926.62,174.312,972.183,122.883,268.032,246.641,630.161,528.53804.84696.441,523.6684.14133.65959.44-267.19-572.84-712.49392.44-431.59-179
Net Income 771-609.84,139.368,358.698,982.465,744.566,428.065,756.534,314.85-577.641,090.41,527.27145.612,297.194,214.612,831.764,004.942,2801,296.751,191.93782.37
Net Income Ratio 0.012-0.010.0680.140.10.0640.0870.10.076-0.010.0190.030.0030.0670.1110.080.1610.1260.0860.1020.091
EPS 4.87-3.8326.0152.4856.3936.141.2536.9325.1-3.636.859.590.9114.4228.5618.326.515.179.039.416.35
EPS Diluted 4.86-3.8326.0152.4856.3936.141.2536.9125.08-3.636.859.590.9113.0424.6615.7721.3512.48.168.96.35
EBITDA 9,0088,268.311,536.1515,211.819,825.7717,749.0315,328.7813,362.2212,642.076,823.5610,084.9910,605.729,444.595,385.427,931.017,072.866,408.722,944.332,390.911,816.291,624.38
EBITDA Ratio 0.1340.1330.190.2550.2210.1970.2060.2320.2220.1180.1760.2060.2190.1570.210.2010.2570.1630.1590.1550.189